13-valent Pneumococcal conjugate vaccine

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Conditions

Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Trial Timeline

Aug 1, 2014 → Jul 1, 2015

NCT ID

NCT02034877

About 13-valent Pneumococcal conjugate vaccine

13-valent Pneumococcal conjugate vaccine is a approved stage product being developed by Pfizer for Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC. The current trial status is completed. This product is registered under clinical trial identifier NCT02034877. Target conditions include Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05329259	Approved	Completed	Oct 6, 2022	Nov 30, 2022	Pneumococcal Disease
NCT03571607	Phase 3	Completed	Jul 12, 2018	Nov 16, 2018	Pneumococcal Infections
NCT02034877	Approved	Completed	Aug 1, 2014	Jul 1, 2015	Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
NCT01026038	Phase 3	Completed	Apr 1, 2010	Nov 1, 2010	13-valent Pneumococcal Vaccine
NCT00963235	Phase 3	Completed	Nov 1, 2009	May 1, 2012	HIV Infections
NCT00708682	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Vaccines, Pneumococcal
NCT00500357	Phase 3	Completed	Nov 1, 2007	Jan 1, 2010	Vaccines, Pneumococcal Conjugate Vaccine
NCT00452452	Phase 3	Completed	Jul 1, 2007	Mar 1, 2008	Pneumococcal Infections
NCT00464945	Phase 3	Completed	Jun 1, 2007	Sep 1, 2008	Pneumococcal Vaccines
NCT00269672	Phase 2	Completed	Sep 1, 2005	Feb 1, 2007	Vaccines, Pneumococcal Conjugate Vaccine

Competing Products

20 competing products in Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

See all competitors

Product	Company	Stage	Hype Score
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	77
Mifepristone	Eli Lilly	Phase 2	52
EXANTA	AstraZeneca	Phase 2	52
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	23
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	77
Esomeprazole + Placebo	AstraZeneca	Phase 3	77
PCV15	Merck	Pre-clinical	23
Raltegravir	Merck	Approved	85
RotaTeq (V260) + IPV	Merck	Phase 3	77
V501	Merck	Phase 3	77
Zostavax	Merck	Phase 3	77
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	77
Letermovir + Placebo	Merck	Phase 3	77
Meningococcal C conjugate vaccine	Novartis	Approved	85
Enteric-coated mycophenolate sodium	Novartis	Phase 3	77
Meningococcal C conjugate vaccine	Novartis	Approved	85
rMenB+OMV NZ	Novartis	Phase 3	77
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	77
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	77
Meningococcal C Conjugate Vaccine	Novartis	Phase 3	77

Other Products from Pfizer